⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10308638 | 0.78 | — | — | |
| SCHEMBL575594 | 0.73 | — | — | |
| SCHEMBL6123574 | 0.72 | — | — | |
| SCHEMBL1978395 | 0.71 | — | — | |
| SCHEMBL1717056 | 0.71 | — | — | |
| SCHEMBL17863679 | 0.70 | CA2 (0.36) | — | |
| SCHEMBL13608350 | 0.67 | — | — | |
| SCHEMBL756080 | 0.67 | — | — | |
| SCHEMBL686401 | 0.64 | CA2 (0.31) | — | |
| SCHEMBL8827943 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277570-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-11707471-B2 | ENPP1 inhibitors and their use for the treatment of cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230190927-A1 | ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE | CYANA THERAPEUTICS LLC | 2023-06-22 | — | — | US | disclosed |
| US-9024014-B2 | Phosphorus-containing compounds and uses thereof | ARIAD PHARMACEUTICALS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20120178714-A1 | Phosphorus-containing Compounds & Uses Thereof | ARIAD PHARMACEUTICALS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20090253648-A1 | Tricyclic-Nucleoside Compounds for Treating Viral Infections | SMITHKLINE BEECHAM CORPORATION (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090208457-A1 | Tricyclic-Nucleoside Prodrugs for Treating Viral Infections | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-20 | — | — | US | disclosed |
| US-7534771-B2 | Tricyclic-nucleoside prodrugs for treating viral infections | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-19 | — | — | US | disclosed |
| US-7524825-B2 | Tricyclic-nucleoside compounds for treating viral infections | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
| US-20090088371-A1 | COMBINATION THERAPY WITH SYK KINASE INHIBITOR | RIGEL PHARMACEUTICALS, INC. | 2009-04-02 | — | — | US | disclosed |
| US-20090048189-A1 | TRICYCLIC-NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. | 2009-02-19 | — | — | US | disclosed |
| US-7414031-B2 | 5-nitro-nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7405204-B2 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20070167383-A1 | NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. | 2007-07-19 | — | — | US | disclosed |
| US-7244713-B2 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7202223-B2 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7157434-B2 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. (US) | 2007-01-02 | — | — | US | disclosed |